download-1A-1.png

Medacta Emphasizes Flexibility for Surgeons and Patients Alike With Launch of MOTO Medial Partial Knee, Medacta Shoulder System and MasterLoc Lateralized Plus at AAOS

Posted On March 6, 2018 By OrthoSpineNews In Recon /  

March 06, 2018

NEW ORLEANS–(BUSINESS WIRE)–Medacta® International, the privately held family-owned global leader in the design of innovative joint replacement and spine surgery products, today launched its new MOTO™ Medial Partial Knee System, Medacta Shoulder System and a third offset option for its MasterLoc™ Hip System at the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting, held March 6-10 in New Orleans, Louisiana. The company will be showcasing these products at Booth #6329 and will also be co-sponsoring a guest reception honoring Italy’s contributions to orthopedic innovation.

“Medacta remains focused on delivering new and innovative orthopedic solutions paired with hands-on support, solid education programs and expert mentorship to help surgeons more efficiently and effectively meet their patients’ needs,” said Francesco Siccardi, executive vice president of Medacta International. “With our MOTO Knee, Shoulder System and MasterLoc LAT PLUS, we’re making it easier for surgeons to treat complex cases or patients with hard-to-match anatomies and optimizing procedures for the outpatient setting to meet growing demand.”

MOTO Partial Knee System: Enabling Superior Fit, Balance and Alignment

Medacta’s MOTO Medial Partial Knee System is a compartment-specific, fixed-bearing solution for partial knee replacement, or unicompartmental knee arthroplasty (UKA), in which only a portion of the knee is resurfaced. Partial knee replacements are rapidly becoming a common choice for orthopedic surgeons seeking to offer patients the option of pain relief in the outpatient setting. With patient demand on the rise, Medacta designed the MOTO System and detailed education platform to simplify common procedural challenges and make partial knee cases easier to perform in an outpatient setting.

The MOTO implants are designed for each specific compartment using an anthropometric database of more than 45,000 CT and MRI knee scans to optimize anatomic coverage, contours, size range and precise fit. Perhaps the most distinguishing feature of MOTO is the instrumentation that allows for precise bone resections to balance knee flexion-extension gap mismatch, while maintaining slight alignment under-correction.

“There was still much to be improved in partial knee arthroplasty,” said J. Mandume Kerina, MD, founder of Unova Health Clinic in Lady Lake, Florida and co-designer of the MOTO Partial Knee, who has been performing outpatient knee replacements for more than a decade. “Based on registry data and results, the MOTO Partial Knee was designed following the fixed-bearing, round-on-flat design, but improves upon the options and flexibility built into the system. The result – an anatomic design, optimized sizing options, logical instrumentation and a versatile surgical technique – gives surgeons more control than before and better addresses challenging patient anatomies.”

In keeping with its commitment to surgeon education and training, Medacta created a unique education program around the MOTO Partial Knee that provides top-level medical education and continuous support to ensure surgeons transitioning to using the implant have adequate support and are able to deliver the best possible outcomes to their patients.

Medacta Shoulder System: Featuring Anatomic and Reverse Options for Complex Cases

The Medacta Shoulder System is a modular solution designed to address the unique challenges around complex shoulder arthritis. Developed by an international team of expert surgeons, the platform offers both Anatomic and Reverse Shoulders to deliver the modularity and compatibility demanded by today’s marketplace. Its unparalleled implant selection allows for an anatomic fit for a wide range of pathologies, with other options including wide-ranging sizes, adjustable offsets and other innovative configurations.

Medacta’s first foray in the shoulder surgery market, the platform was unveiled in February 2017 following its first ever surgery in Europe, while its first U.S. surgery took place in the fall of 2017. The system is now available for surgeons throughout the United States and Europe.

MasterLoc LAT PLUS: Providing Unmatched Offset Range for Optimal Restoration

With the addition of the LAT PLUS, Medacta’s MasterLoc Hip System is the only flat-tapered wedge stem for total hip replacement with a unique progressive triple offset, giving surgeons more options to better suit their patients’ needs without impacting leg length. Adding to the MasterLoc’s existing standard offset (STD) and lateralized version (LAT), which adds an extra six millimeters of femoral offset to the STD, the LAT PLUS offers another five millimeters of offset to help surgeons enhance component stability.

The MasterLoc Hip System was introduced in November 2016 as another addition to Medacta’s cementless implant portfolio. The MasterLoc features Medacta’s Mectagrip plasma-sprayed titanium coating, designed to enhance initial fixation with its high coefficient of friction and the potential long-term stability inherent to titanium plasma-sprayed devices.

Guest Nation Reception at AAOS: Honoring Italy’s Contributions

Medacta International is also co-sponsoring the 2018 Guest Nation Reception honoring Italian orthopedic professional attendees at AAOS. The Boards of Directors of the Italian Society of Orthopaedics and Traumatology (SIOT) and of AAOS will be present among more than 200 guests. The reception will take place on Friday, March 9, 2018 from 6:30-8:30 p.m. Eastern.

About Medacta International

Medacta® International is a world leading manufacturer of orthopedic implants, neurosurgical systems, and instrumentation. Medacta’s revolutionary approach and responsible innovation have resulted in standard of care breakthroughs in hip replacement with the AMIS® system and total knee replacement with MyKnee® patient matched technology. Over the last 10 years, Medacta has grown dramatically by taking a different approach and placing value on all aspects of the care experience from design to training to sustainability. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 30 countries. To learn more about Medacta International, please visit www.medacta.com or follow @Medacta on Twitter.

Contacts

For Medacta International
Jill Bongiorni, 516-729-2250
Jill@torchcomllc.com

Read More

Materialise to Launch TRUMATCH® Personalized Solutions Shoulder System

Posted On March 6, 2018 By OrthoSpineNews In Recon /  

March 06, 2018

PLYMOUTH, Mich.–(BUSINESS WIRE)–Materialise NV (Nasdaq:MTLS) launched a shoulder planner for surgeons with the possibility to plan shoulder arthroplasty cases and order patient-specific shoulder guides, in collaboration with DePuy Synthes. The TRUMATCH® Personalized Solutions Shoulder System, revealed at the AAOS Annual Meeting in New Orleans, marks a further extension of Materialise’s longstanding collaboration with DePuy Synthes, who will distribute the solution in the United States, Canada, Australia, New Zealand and Europe.

The TRUMATCH® Personalized Solutions Shoulder System will help orthopaedic surgeons prepare for shoulder arthroplasty surgery, specifically addressing Reverse Shoulder Arthroplasty (RSA) and Anatomic Total Shoulder Arthroplasty (TSA) operations. It offers surgeons an all-in-one, web-based platform that allows them to better plan and prepare for these operations as well as order patient specific 3D printed surgical guides.

RSA and TSA operations present unique challenges, with limited visibility as the result of the small incision, the Glenoid cavity being deep in the surgical window and the lack of reliable landmarks. However, precise alignment is required, not just because of limited bone stock, but because of its impact on overall screw length and fixation (with RSA) and the occurrence of peg perforation (with TSA).

Compared to using 2D images to diagnose and perform a shoulder arthroplasty, pre-surgical planning lets surgeons know what to expect upfront, working in three dimensions. With 3D virtual pre-surgical planning, implant positioning is done within a stable reference frame, linked to the entire scapula, using reliable landmarks that are not subject to case specific wear patterns. This allows the surgeon to be more precise in the alignment of the implant and screw positioning, improving overall fixation. The measurement, viewing and implant positioning features of the TRUMATCH® Personalized Solutions Shoulder System helps surgeons make better informed, clinical decisions before, rather than during surgery, taking control of an important step for a more desired outcome. This increased pre-operative preparedness gives the surgeon and the team more confidence and control during surgery.

As a result of the pre-operative planning, surgeons may decide to execute the surgery with personalized guides if it’s believed that conventional instruments or standard guides are less appropriate because of glenoid deformities. The TRUMATCH® Personalized Solutions Shoulder System also allows surgeons to order patient specific 3D printed shoulder guides within the same platform.

“3D planning is gaining popularity with orthopaedic surgeons performing shoulder operations,” said Wilfried Vancraen, Founder and CEO of Materialise. “Together with our strategic partners like DePuy Synthes, we are continually working to improve surgical planning processes for a range of operations. We are proud that this expanded collaboration will empower even more orthopaedic surgeons to discover the benefits of online planning and 3D-printed, patient-specific surgical guides.”

Materialise is exhibiting during the annual meeting for the American Academy of Orthopaedic Surgeons, March 6-10, 2018 in New Orleans. The company hosts live software demonstrations and expert talks on booth #3729 as well as a lunchtime presentation on March 7 in the Technology Theatre. Learn more at http://www.materialise.com/en/medical/orthopaedic-surgeons-meeting-2018.

About Materialise
Materialise incorporates 27 years of 3D printing experience into a range of software solutions and 3D printing services, which together form the backbone of the 3D printing industry. Materialise’s open and flexible solutions enable players in a wide variety of industries, including healthcare, automotive, aerospace, art and design, and consumer goods, to build innovative 3D printing applications that aim to make the world a better and healthier place. Headquartered in Belgium, with branches worldwide, Materialise combines the largest group of software developers in the industry with one of the largest 3D printing facilities in the world. For additional information, please visit: www.materialise.com.

About Materialise’s Medical Division
Materialise Medical, which has pioneered many of the leading medical applications of 3D printing, enables researchers, engineers and clinicians to revolutionize innovative patient-specific care. Materialise Medical’s open and flexible platform of software and services, Materialise Mimics, forms the foundation of certified Medical 3D Printing, in clinical as well as research environments, offering virtual planning software tools, 3D-printed anatomical models, and patient-specific surgical guides and implants. For additional information, please visit: medical.materialise.com.

Cautionary Statement on Forward-Looking Statements
Some of the statements in this press release are “forward-looking” and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements relating to, among other things, our planned commercialization efforts and regulatory approvals of our technologies as well as the success thereof and our research and development projects. These forward-looking statements are based upon the expectations of management under current assumptions at the time of this press release. We caution you that forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control that may cause our actual results to differ materially from our expectations. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this presentation as a result of new information, future events or otherwise, unless we have obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.

Contacts

Press Contacts:
Materialise
Virginia Goble
Vice President Marketing-North America
Mobile: (248) 921-5500
Email: virginia.goble@materialise.com or press@materialise.com
Twitter: @MaterialiseNV
Visit: www.materialise.com
or
Franco
Megan Peterson
Mobile: 248.330.9807
Email: peterson@franco.com

Photo credit: Materialise

Read More
922_main-1.jpg

MicroPort Orthopedics Celebrates 20 Years of Stability with its Medial-Pivot Total Knee System

Posted On March 6, 2018 By OrthoSpineNews In Recon, Top Stories /  

March 06, 2018

ARLINGTON, Tenn.–(BUSINESS WIRE)–MicroPort Orthopedics Inc., a medical device company that develops and manufactures cutting-edge joint replacement implants designed to help patients achieve full function faster, is celebrating 20 years of market experience with its medial-pivot total knee system. Since launching in 1998, over 550,000 patients have benefited from MicroPort’s medial-pivot technology, which touts compelling long-term clinical results.

“The medial-pivot knee system has now stood the test of time at 20 years demonstrating impressive survivorship and excellent patient satisfaction,” said C. Lowry Barnes, MD, Chair of Orthopedic Surgery at the University of Arkansas for Medical Sciences. “It is important to recognize that this isn’t just one single publication. Over the years, the Advance® and Evolution® Medial-Pivot Knee Systems have been included in over 90 peer-reviewed publications that validate its long-term durability and functionality.”

For many years, orthopedists have clung to the concept of a hinge-like knee design with multiple radii. However, studies show that on average, 20% of patients are not satisfied with the outcome of their total knee replacement. Challenging these traditional knee designs, pioneers such as J. David Blaha, MD, Mr. Michael Freeman, MD, and Richard Komistek, PhD provided kinematic and radiographic evidence supporting medial-pivoting kinematics and stability of the knee, paving the way for the release of MicroPort’s medial-pivot knee system.

“I began using MicroPort’s medial-pivot knee system in May of 1998,” said Joost Lagast, MD, Orthopedic Surgeon at Maria Middelares Hospital Ghent. “At the time, I was not 100% satisfied with my results and was looking for something new. I attended a meeting with Professor Blaha at AAOS and was very impressed with the medial-pivot concept. During my first case, it was love at first sight – the stability and natural motion were unlike anything I’d seen in my practice. Over the last 20 years, I’ve performed nearly 4,000 knee replacement surgeries using the system, and I’m still fantastically in love with it today.”

The Evolution® Medial-Pivot Knee System features medial ball-in-socket articulation and a mobile lateral compartment that pivots about the medial side, enhancing stability, providing high flexion, and allowing the prosthesis to replicate the natural feel and motion of the knee. Additionally, the medial stability of the Evolution® knee substitutes for both the ACL and PCL, allowing for normal quadriceps function and increased proprioception.

Former NFL quarterback and Hall-of-Famer, Terry Bradshaw, underwent total knee replacement surgery with the Evolution® Medial-Pivot Knee. “My knee was causing me all kinds of problems. I couldn’t sleep at night, I couldn’t take the stairs, and worst of all, I had a hard time playing with my granddaughter,” said Bradshaw, now 69 years old. “I underwent surgery on a Tuesday, left the hospital two days later, and was walking without assistance in two weeks. Today, I can do anything I want to do – walking down stairs, squatting, fishing, and golfing. The medial-pivot technology has been life changing for me. It feels just like my knee!”

“MicroPort Orthopedics is proud to celebrate the 20th anniversary of our medial-pivot knee system,” said Aurelio Sahagun, President, MicroPort Orthopedics. “When we launched the system back in 1998, there was nothing else like it on the market – it challenged the basis of traditional designs. Change does not happen often in orthopedics, but at the time, we knew that the medial-pivot concept had the capability to revolutionize total knee replacement. 20 years later, clinical results have proven that this design delivers better outcomes for patients and surgeons. It is incredibly gratifying to offer a best-in-class knee replacement option, and we are looking forward to another 20 years of innovation as we expand the medial-pivot technology into the revision market.”

About MicroPort Orthopedics

Established in January 2014, MicroPort Orthopedics Inc. is a multinational producer of orthopedic products and a proud member of the MicroPort Scientific Corporation family of companies. From its headquarters in Arlington, Tennessee, MicroPort Orthopedics develops, produces, and distributes innovative orthopedic reconstructive products. The company’s U.S.-based manufacturing and logistics capabilities deliver high quality hip and knee products to patients and their doctors in over 60 countries, including the U.S., EMEA, Japan, Latin America, and China markets. For more information about MicroPort Orthopedics, visit http://www.ortho.microport.com/.

About MicroPort Scientific

MicroPort Scientific Corporation is a leading medical device company focused on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, MicroPort maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort is dedicated to becoming a patient-oriented global enterprise that improves and reshapes patient lives through application of innovative science and technology. For more information, please refer to: http://www.microport.com.

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words “believe,” “intend,” “expect,” “anticipate,” “project,” “estimate,” “predict,” “is confident,” “has confidence” and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort’s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

 

Contacts

MicroPort Orthopedics
Alex Piersiak, 617-909-5022
Alex.piersiak@ortho.microport.com

 

 

Read More
ConforMIS-Logo3-A-1.jpg

Conformis iTotal CR Knee Replacement System Awarded “3A” Rating from the Orthopaedic Data Evaluation Panel in the United Kingdom

Posted On March 1, 2018 By OrthoSpineNews In Recon, Top Stories /  

BILLERICA, Mass., March 01, 2018 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ:CFMS), a medical technology company that offers joint replacement implants designed and manufactured to fit and conform to each patient’s unique anatomy, today announced that the Orthopaedic Data Evaluation Panel in the United Kingdom (ODEP) (http://www.odep.org.uk/ODEPExplained.aspx)awarded the Conformis iTotal CR knee replacement system a “3A” rating.  The 3A rating is based on strong evidence of implant performance over three years, including low revision rates as indicated in the United Kingdom’s National Joint Registry.

ODEP is an independent panel of leading orthopedic surgeons and experts in the UK that evaluates data related to use of hip and knee implant technologies and provides a rating to indicate performance in key areas including survivorship. ODEP provides the National Health Service (NHS) with an approved list of products that meet the revision rate standard set by the National Institute for Health and Care Excellence (NICE) in the United Kingdom. The 3A rating (as explained in more detail at http://www.odep.org.uk/ODEPExplained.aspx#2) is based on three-year performance data. ODEP ratings provide a simple, independently verified assessment as to the performance of an implant, assessed against national clinical best practice guidelines. This enables clinicians to ensure that the implants that they use comply with these national guidelines.  Only products that demonstrate compliance with NICE guidance are awarded a rating.

“The positive ODEP 3A rating reaffirms my experience treating patients with the Conformis iTotal CR knee replacement system, which I believe offers my patients a more natural feeling knee with improved performance and mobility,” said Mr. Ian McDermott FRCS, Senior Consultant Knee Surgeon at London Sports Orthopaedics, based at the London Bridge Hospital in London, UK. “The clinical evidence and three-year survivorship data together are consistent with the improvement I am seeing with my patients’ outcomes after knee replacement surgery using Conformis knee prostheses.”

“ODEP ratings provide a reliable, simple and independent assessment of the performance of an implant” said, Mr. Fahad G. Attar, MBChB, FRCS, Consultant Trauma & Orthopaedic Surgeon at BMI Alexandra and Whiston Hospital, St. Helens & Knowsley Teaching Hospitals, United Kingdom. “I expect that this 3A rating will now provide additional reassurance and peace of mind to my patients and reinforce the performance reputation of Conformis iTotal CR knee replacement implants that contribute to the improved clinical outcomes I am seeing in my practice.”

“The ODEP awarded the Conformis iTotal CR system a 3A rating based in part on positive implant survivorship and performance data from the UK National Joint Registry at three years’ post-surgery,” said Mark Augusti, Chief Executive Officer and President of Conformis.  “This rating provides another independent verification that our design philosophy, predicated on patient conforming implants, results in performance where it counts the most, in patients.  “We hope that this 3A rating also provides an opportunity for Conformis to expand our product offering to more patients receiving their healthcare in NHS facilities.”

More information on the ODEP can be found on their website at http://www.odep.org.uk/ODEPExplained.aspx

About Conformis, Inc.

Conformis is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are designed and manufactured to fit and conform to each patient’s unique anatomy.  Conformis offers a broad line of patient conforming total and partial knee systems that include sterilized single-use instruments delivered in a single package to the hospital.  Conformis owns or exclusively in-licenses approximately 420 issued patents and pending patent applications that cover customized implants and patient-specific instrumentation for all major joints.

For more information, visit www.conformis.com

Cautionary Statement Regarding Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Conformis, including statements about the ability to offer implants to patients in the United Kingdom, that potential clinical benefits or other impacts and advantages of using customized implants, as well as other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar expressions, constitute forward-looking statements within the meaning of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make as a result of a variety of risks and uncertainties, including risks related to our clinical studies, and the other risks and uncertainties described in the “Risk Factors” sections of our public filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Conformis views as of the date hereof. Conformis anticipates that subsequent events and developments may cause Conformis’s views to change. However, while Conformis may elect to update these forward-looking statements at some point in the future, Conformis specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Conformis’ views as of any date subsequent to the date hereof.

MEDIA CONTACT
Kelly Wakelee
Berry and Company Public Relations
kwakelee@berrypr.com
212.253.8881

INVESTOR RELATIONS CONTACT
Oksana Bradley
Investor Relations
ir@conformis.com
781.374.5598
www.conformis.com

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/acfb1db3-b005-40af-8b6e-dffa8c838cfe

 

Read More
Screen-Shot-2018-02-23-at-1.16.48-PM.png

Ortho Sales Partners Announces Two Executive Additions and the Formation of Two Divisions (Orthopedics and Spine)

Posted On February 23, 2018 By OrthoSpineNews In Recon, Spine, Top Stories /  

Ortho Sales Partners, the global leader in commercialization services for the orthopedic industry, is pleased to announce key additions allowing the formation of two separate divisions. This strategic move further demonstrates Ortho Sales Partners commitment to offer the industries most talented and experienced consultants to its clients. In advance of their presence at the American Academy of Orthopedic Surgeons annual conference (Booth 5713), Ortho Sales Partners announces the formation of two distinct divisions. One for Orthopedics and the other for Spine. Hired to lead the Orthopedic division are Jeff Chandler and Dan Darges.

Jeff Chandler, has been appointed General Manager of Orthopedics. Mr. Chandler has a rich history in commercializing products in Total Joint Reconstruction, Trauma and Sports Medicine. A key entrepreneurial career highlight featured Mr. Chandler as Founder & CEO/President of a venture capital backed medical device firm (Aquarius Medical), led the Company for six years incepting two core technologies (fluid management pump; core body thermoregulation from Stanford University OTL), and through product inventions (IP), funding, research, development, regulatory, manufacturing, commercialization, and into a successful exit.

About his joining Ortho Sales Partners, Jeff Chandler said: “I’m excited to bring a novel and cost-effective commercialization model to startup and emerging growth companies, or launching disruptive technologies for established medical device firms. In the entrepreneurial spirit of preserving expensive cash, OSP provides an attractive staged-based vehicle to deploy a multi-disciplined and highly networked senior level team in comparison to being confined by traditionally limited FTE hiring.”

Dan Darges, Vice President of Orthopedics, career started in 1997 with Smith & Nephew as a Ortho Recon/Trauma rep, Mr. Darges’ successes and reputation led him to accept an offer as a Regional Sales Director for a top Arthrex Distributorship in 2002.  Working for a Distributor allowed Mr. Darges to grow skills as a leader and manager for both Arthrex and Wright Medical product lines in Multiple States.  In 2007, Mr. Darges founded Bio-Surg Solutions, Inc., a Distributorship for Wright Medical.  After many successful years as one of the highest growth distributorships in the country, Mr. Darges sold his Distributorship to Wright Medical in 2012 and became a Senior Director of Sales for Wright Medical’s Foot and Ankle/Biologics products.

“I am really excited to be part of the Ortho Sales Partners team” said Darges. “I feel this role allows me to use my skill sets in multiple facets for multiple companies within the orthopedic industry.  I have enjoyed my time thus far as a consultant and look forward to taking on more responsibility for our clients as the Vice President of Orthopedics.”

For the spine division, Ortho Sales Partners has promoted Matt Stuttle to the position of General Manager. Mr. Stuttle has been in the medical industry for over 18 years. He began his career in spine in 2003 has held executive management positions at Kyphon (acquired by Medtronic in 2008 for $4.3B), Paradigm Spine, SpineWave and most recently Spineart.

“I feel strongly that Ortho Sales Partners is well positioned to facilitate guidance, structure, growth and scale to medical companies worldwide. Our strengths lie in our team; A world class organization of experienced executives across a broad spectrum of specialties, all designed to mitigate risk and speed execution. I’ve had the pleasure of knowing and working closely with Kevin over the last 15 years. His leadership and vast experience lends itself well to the core focus of Ortho Sales Partners; Creating immense value for our clients and their respective shareholders.”

As General Manager’s Jeff and Matt will report in to the CEO, Kevin McGann.

“We welcome Jeff and Dan to Ortho Sales Partners. As we continue to grow our business, it is important we structure and scale the organization that allows for the continued focus on our clients and positive outcomes. Having Matt and Jeff lead our Spine and Orthopedic Divisions will allow us to stay focused while utilizing their experience and leadership skills.”

About Ortho Sales Partners

Ortho Sales Partners has created a unique platform to help companies in any stage commercialize their products in a very efficient way. We have worked closely with many organizations and produced results that have profoundly impacted each client’s business.

Our services are geared to meet you where you are today and help your business grow by utilizing proven industry executives that bring you an objective analysis and recommendations going forward. Our market knowledge is based on current trends and competitive analysis from industry stalwarts from some of the highest growth companies.

Ortho Sales Partners’ headquarters are in Scottsdale, Arizona but we have several offices across the US. (http://www.orthosalespartners.com).

Read More
1-4.jpg

Opening of FX Shoulder USA: the French Shoulder Arthroplasty Specialist

Posted On February 20, 2018 By OrthoSpineNews In Recon, Top Stories /  

DALLAS, February 20, 2018 /PRNewswire/ —

FX Solutions, French number two in shoulder arthroplasty, has established an US subsidiary named FX Shoulder USA, Inc. to further expand directly into the US markets and to provide its current and future United State clients with an unique, large and innovative offer of shoulder implants.

FX Shoulder USA, based in Dallas, TX, was formed to proudly be the exclusive distributor for FX Solutions products effective January 1, 2018.

Created in 2011, FX Solutions has generated an annual growth of its turnover of more than 60% since its creation and plans to keep the same growth in 2018, particularly in the United States.

Its products have been approved in the USA since 2016 with the Humelock II, its only lockable shoulder trauma prosthesis available in the US. In January 2017, FX Solutions further expanded its portfolio with the introduction of the Humelock Reversed, a 145° reverse angle (available since 2011 in Europe). Additionally, in June 2017 it’s short stem Humeris was released as its primary platform.

FX Shoulder USA has quickly built a strong network of surgeons and distributors in Florida, Pennsylvania, Rhode Island, Maryland, Georgia and Texas and looks to further expand its distribution across the Midwest and West Coast. The group has strong growth ambitions and aims to develop rapidly in North America, the world’s largest market for shoulder prostheses.

FX Shoulder USA is the only company worldwide, and especially in the United States, to focus exclusively on shoulder arthroplasty. With a very technical and customer service-oriented approach, the company offers the best choice in shoulders replacement, adapted to any procedure the surgeon would require.

FX Shoulder USA will exhibit at the American Academy of Orthopedic Surgeons (AAOS) March 6-10, 2018 in New Orleans at booth n°3158 and at the American Shoulder and Elbow Surgeons (ASES) in Chicago in October 2018.

http://www.fxshoulder.com

1-800-280-0775
info@fxshoulder.com

SOURCE FX Shoulder USA, Inc

 

(Logo: https://mma.prnewswire.com/media/642925/FX_Shoulder_USA_Logo.jpg )

(Photo: https://mma.prnewswire.com/media/643325/FX_Shoulder_USA_Humeris.jpg )

Read More
shutterstock_130092953-1-1080x627.jpg

Shoulder Arthroplasty Market Global Growth Forecast at 6.12% CAGR to 2022

Posted On February 16, 2018 By OrthoSpineNews In Recon /  

PUNE, India, February 16, 2018 /PRNewswire/ —

ReportsnReports.com adds Global Shoulder Arthroplasty Market 2018-2022 report that says one driver in the market is growing prevalence of arthritis coupled with increasing geriatric population. The geriatric population is prone to degenerative bone diseases like arthritis and osteoporosis. The increasing prevalence of arthritic conditions such as rheumatoid arthritis and the high occurrences of bone fractures among the geriatric population drive the growth of this market. Geriatric population is increasing across the world.

Get complete report on Shoulder Arthroplasty Market spread across 127 pages, analyzing 5 major companies and providing 82 data exhibits now available at http://www.reportsnreports.com/reports/1346596-global-shoulder-arthroplasty-market-2018-2022.html .

The analysts forecast global shoulder arthroplasty market to grow at a CAGR of 6.12% during the period 2018-2022. One trend in the market is growing utilization of robotics in surgeries. Robotics is being increasingly utilized to improve surgical outcomes for patients. The use of robotics in surgeries reduce hospital stays and lowers the rate of complications. It also helps surgeons perform surgical procedures with more precision, accuracy, flexibility, and control when compared with conventional techniques.

Main companies in the global shoulder arthroplasty market: DePuy Synthes, Integra LifeSciences, Smith & Nephew, Wright Medical Group, and Zimmer Biomet. The shoulder joint is a highly mobile joint. It comprises four joints, namely the sternoclavicular joint, scapulothoracic joint, acromioclavicular joint, and glenohumeral joint. Shoulder arthroplasty is a surgical procedure for partial or total replacement of the glenohumeral joint by a prosthetic implant. The surgery is conducted to relieve arthritic shoulder pain and fix severe joint damage due to injury.

Order a copy of Global Shoulder Arthroplasty Market 2018-2022 report at http://www.reportsnreports.com/purchase.aspx?name=1346596 .

Further, the report states that one challenge in the market is high cost of technological development. The high cost of technological development can affect the growth of the global shoulder arthroplasty market. Due to technological advances, the cost of shoulder arthroplasty and associated devices is increasing. This report covers the present scenario and the growth prospects of the global shoulder arthroplasty market for 2018-2022. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

Another related report is Global Inferior Vena Cava (IVC) Filters Market 2018-2022, the analysts forecast global inferior vena cava (IVC) filters market to grow at a CAGR of 11.24% during the period 2018-2022. Key players in the global inferior vena cava (IVC) filters market: Argon Medical Devices, B. Braun Melsungen, Boston Scientific, C. R. Bard, and Cook Medical.

According to the inferior vena cava (IVC) filters market report, one driver in the market is increasing incidence of venous thromboembolism (VTE). The incidence of VTE and its related risk factors is increasing globally. VTE is a combination of a PE and DVT. DVT is a medical condition that occurs when a blood clot forms in a deep vein. PE is a medical condition in which a clump of material, usually a blood clot, gets wedged into an artery of the lung. There are more than nine million cases of VTE every year globally. Browse complete Inferior Vena Cava (IVC) Filters Market report at http://www.reportsnreports.com/reports/1346580-global-inferior-vena-cava-ivc-filters-market-2018-2022.html .

Explore other new reports on Medical Devices Market at http://www.reportsnreports.com/market-research/medical-devices/ .

About Us:

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Contact:
2nd Floor, Metropole Building,
Next to Inox Theatre,
Bund Garden Road, Pune – 411013.
Maharashtra, India.
+1-888-391-5441
sales@reportsandreports.com

Connect with Us:
LinkedIn: http://www.linkedin.com/company/reportsnreports
RSS/Feeds:  http://www.reportsnreports.com/feed/l-latestreports.xml

SOURCE ReportsnReports

Read More
For-PR.jpg

ORTHALIGN ANNOUNCES CLINICAL MILESTONE HAVING PERFORMED 75,000 JOINT ARTHROPLASTY CASES

Posted On February 15, 2018 By OrthoSpineNews In Recon /  

Aliso Viejo, CA, Feb. 15, 2018 (GLOBE NEWSWIRE) — OrthAlign, Inc., a leading provider of orthopedic surgical navigation solutions, is proud to announce a clinical milestone with 75,000 navigation-assisted joint replacement surgeries. OrthAlign’s hand-held sensor-based technologies support a wide array of indications including total knee replacement, partial knee replacement and total hip replacement. The company’s flagship application, KneeAlign® for total knee replacement, provides both tibial and femoral intra-operative navigation in a simple, palm-sized, single-use device.

The KneeAlign application is compatible with all standard implant systems. The UniAlign™ application launched in early 2017 leveraging the clinical success of KneeAlign, and allowing for seamless transitions between partial and total knee replacement interventions. In 2017, the Company also introduced HipAlign® for total hip replacement into limited market evaluation. The HipAlign application provides cup navigation and measures changes in leg length and will be fully commercially available in 2018.

“We are thrilled to pass this significant milestone, building and servicing technologies that have assisted surgeons worldwide in completing more than seventy-five thousand successful arthroplasty surgeries,” said Eric Timko, Chairman and CEO of OrthAlign. “In ORs around the world, OrthAlign has become a trusted and reliable tool that our customers depend on to achieve their desired results.”

“What is remarkable about OrthAlign’s technology is that every post-operative result is consistent, every x-ray looks the same,” noted David Mayman, Co-Director of Computer Assisted Surgery at Hospital for Special Surgery. “I’m impressed by the rate of innovation happening at the company right now. The clinical advantage, along with the economics of the single-use disposable model, makes OrthAlign well poised for continued growth.”

ORTHALIGN, INC.

OrthAlign is a privately held medical device and technology company, developing advanced technologies that deliver healthier and more pain-free lifestyles to joint replacement patients, globally. We provide healthcare professionals with cutting edge, computer-assisted surgical tools that seamlessly and cost-effectively deliver vital data and clinical results to optimize outcomes for our patients. For more information regarding OrthAlign, please visit www.orthalign.com or contact Adam Simone (asimone@orthalign.com).

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/3bcf00e9-7096-400c-8f72-674ca85a457d

Adam Simone
OrthAlign
asimone@orthalign.com
Read More

Zimmer Biomet’s Rapid Recovery Program Marks Two Decades of Success in Europe

Posted On February 8, 2018 By OrthoSpineNews In Recon /  

WARSAW, Ind., Feb. 8, 2018 /PRNewswire/ — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, is marking the 20th anniversary of Rapid Recovery, an evidence-based program optimizing all aspects of a patient’s care pathway and surgical experience. Zimmer Biomet pioneered Rapid Recovery in 1997 to complement its commercial product offerings and help healthcare providers improve the quality and cost-efficiency of patient care. Zimmer Biomet’s Rapid Recovery program combines the principles of fast-track surgery with evidence-based approaches to process optimization, clinical enhancements, patient engagement, data collection and evaluation, strategy and marketing.

To date, Zimmer Biomet has implemented the Rapid Recovery program in approximately 250 hospitals throughout Europe. A foundation for this success is the clinical evidence on which the program is built. Since 1997, hundreds of papers have been published on fast-track hip and knee arthroplasty1. In the most recently published review, large cost savings were reported, without any increase in complication rates2.

The Rapid Recovery program’s 20-year track record of success is a testament to Zimmer Biomet’s commitment to offering products, services and the latest digital technologies as part of Zimmer Biomet Signature Solutions. The Zimmer Biomet Signature Solutions offering supports the enhancement of the entire continuum of care, from pre-operative patient education to peri-operative efficiencies and post-operative support to promote early mobilization, rehabilitation and discharge.

“What distinguishes Zimmer Biomet’s Rapid Recovery program is not only two decades of expertise working with Europe’s leading, high-performance orthopaedic surgery units, but also the hands-on support capabilities of our dedicated Rapid Recovery teams, access to our advisory board and to the network of European thought leaders in fast-track medicine,” said Katarzyna Mazur-Hofsäss, Zimmer Biomet President, EMEA.

The Rapid Recovery program supports primary hip and knee arthroplasty, outpatient arthroplasty surgery, fragility hip fracture treatment, sports medicine procedures, spine interventions and shoulder arthroplasty.

“The Rapid Recovery program provides a framework for examining and optimizing every component of the surgical process that can impact outcomes – from blood and pain management including peri-operative anesthesia, to tissue-sparing surgical techniques and post-operative physiotherapy regimens,” said Professor Henrik Kehlet, an inaugural member of Zimmer Biomet’s Rapid Recovery Advisory Board, an innovator in fast-track surgery and professor of perioperative therapy at Copenhagen University. “Over the past two decades, Zimmer Biomet has been at the forefront of educating, encouraging and supporting hospitals across Europe to adopt rapid recovery protocols to improve the quality of patient care and drive down avoidable costs. I’m proud to serve on the Rapid Recovery Advisory Board to continue working toward making fast-track protocols the new standard of care in joint replacement surgery.”

About Zimmer Biomet
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; office based technologies; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.

We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information, visit www.zimmerbiomet.com, or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.

ZB-Corp

Cautionary Statement Regarding Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet’s expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes.  Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially.  For a list and description of some of such risks and uncertainties, see Zimmer Biomet’s periodic reports filed with the U.S. Securities and Exchange Commission (SEC).  These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet’s filings with the SEC.  Forward-looking statements speak only as of the date they are made, and Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.  Readers of this news release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate.  This cautionary statement is applicable to all forward-looking statements contained in this news release.

1 Pubmed: terms: fast track surgery arthroplasty, access on 1 feb 2018

2 Wilches C, Sulbarán JD, Fernández JE, Gisbert JM, Bausili JM, Pelfort X. Fast-track recovery technique applied to primary total hip and knee replacement surgery. Analysis of costs and complications. Rev Esp Cir Ortop Traumatol. 2017 Jan 7. pii: S1888-4415(16)30104-7.

SOURCE Zimmer Biomet Holdings, Inc.

Related Links

http://www.zimmerbiomet.com

Read More
OMNI_paramount_450.jpg

New Data and Surgical Experiences with OMNIBotics® Active Spacer™ Ligament Balancing System Presented at Prestigious Orthopaedics Conference

Posted On February 5, 2018 By OrthoSpineNews In Recon /  

RAYNHAM, Mass., Feb. 5, 2018 /PRNewswire/ — OMNIlife science™, Inc. (“OMNI™”), an established medical technology company targeting the $15 billion global hip and knee replacement device market, announced that several presentations about their breakthrough OMNIBotics Active Spacer technology were featured at the International Congress for Joint Reconstruction (ICJR) 10th Annual Hip & Knee Conference held in Vail, CO from January 18-21.

The ICJR focuses on providing a comprehensive orthopaedic learning experience for their members, delivering timely and relevant education. The more than 150 attendees learned about OMNIBotics Active Spacer technology in both a pre-recorded surgery presentation and a podium presentation. The surgery, “TKA Utilizing OMNIBotics Active Spacer Robotically Assisted Ligament Balancing System” was performed and narrated by Jeffrey H. DeClaire, MD, DeClaire LaMacchia Orthopaedic Institute, Rochester Hills, MI. The podium presentation “Ligament Balancing Technology in TKA” was given by John Keggi, M.D., Connecticut Joint Replacement Institute, Hartford, CT.

Dr. DeClaire commented, “With this new technology and the ability to capture accurate data, the Active Spacer can help to more accurately and consistently restore the normal soft tissue balance of the knee with the potential to improve patient outcomes and patient satisfaction.”

The OMNIBotics Active Spacer, with more than 150 procedures performed to date, provides the surgeon with a quantitative tool to actively manage the soft tissue envelope with dynamic real-time feedback. Since sub-optimal soft tissue balancing is a potential contributing factor to patient dissatisfaction with their knee replacement, OMNI developed this device to address that need. When the OMNIBotics Active Spacer is combined with the accuracy of alignment and bone cuts provided by the OMNIBotics system, the result is a completely customized procedure from both a skeletal and a soft tissue perspective.

“The Active Spacer provides the most accurate and useful information to date for achieving good balance in knee replacement patients,” stated Dr. Keggi. “Surgeons can now see the full motion and precise balance of the knee in real time, which provides important feedback to optimize the function of the knee.”

The OMNIBotics Active Spacer received FDA clearance in early September, 2017 and is currently in clinical evaluation at six sites in the United States and one in Australia.

About OMNI

OMNI is a privately held company with a proprietary robotic platform, OMNIBotics®, which allows surgeons to conduct patient-specific total knee surgery designed to enhance patient satisfaction and reduce hospital costs. In addition, OMNI designs, engineers, manufactures and distributes a wide range of proprietary hip and knee implants and is focused on providing cutting edge technologies to transform outcomes in joint replacement surgery and enhance a surgeon’s ability to help patients live active and pain-free lives. For more information about OMNI, please visit www.omnils.com.

Forward-Looking Statements

Statements in this press release concerning the future business, operations and prospects of OMNIlife science, Inc., including its plans specific to OMNIBotics systems, as well as statements using the terms “plans,” “believes” or similar expressions are “forward‐looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based upon management’s current expectations and are subject to a number of factors and uncertainties. Information contained in these forward‐looking statements is inherently uncertain, and actual performance and results may differ materially due to many important factors. Such factors include, among others, changes in competitive conditions and pricing in OMNI’s markets, decrease in the demand for OMNI’s products, delays in OMNI’s product research and development cycles, decreases in the use of OMNI’s principal product lines or in procedure volume, unanticipated issues in complying with domestic or foreign regulatory requirements related to OMNI’s current products or securing regulatory clearance or approvals for new products or upgrades or changes to OMNI’s current products, the impact of the United States healthcare reform legislation on hospital spending and reimbursement, any unanticipated impact arising out of the securities class action or any other litigation, inquiry, or investigation brought against OMNI, increases in costs of OMNI’s sales force and distributors, and unanticipated intellectual property expenditures required to develop, market, and defend OMNI’s products. OMNI cannot guarantee any future results, levels of activity, performance or achievement. OMNI undertakes no obligation to update any of its forward-looking statements after the date of this press release.

Contact

Cindy Holloway, Director of Marketing Communications
Phone: (508) 824‐2444
cholloway@omnils.com

SOURCE OMNIlife science, Inc.

Related Links

http://www.omnils.com

Read More